Mirogabalin Eliminated Pain and Reduced Inflammation in Visceral Pain
Physiological Research · 10.03.2026 · 167
DOI: 10.33549/physiolres.935613 ↗Kurz gefasst
Fachartikel in der Zeitschrift Physiological Research, online erschienen am 10.03.2026. Verfasst von I Yesilyurt und 4 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
Mirogabalin is a newly developed gabapentinoid drug. Several in vivo and clinical studies have demonstrated the potent analgesic effects of mirogabalin in neuropathic pain. This study aims to investigate the impact of mirogabalin on visceral pain and inflammation. Adult male Balb/c mice (20-25 g) were used in the study (n=7). Mirogabalin was administered intraperitoneally at 10, 20, and 40 mg/kg doses. Inflammatory visceral pain was induced by intraperitoneal administration of acetic acid. The number of writhing was observed after acetic acid administration, and the effective dose of mirogabalin was determined. In the second phase of the study, the effects of mirogabalin on locomotor activity and leukocyte infiltration into peritoneal tissue were examined. IL-6, GSH levels, and SOD activity were investigated biochemically. Statistical analyses were performed in the GraphPad Prism (v8.0.1) program. Mirogabalin was significantly antinociceptive at all three doses (p
Zitieren
APA
Yesilyurt, I., Bitikas, S., Yigit, S., Gulakar, B., & Gul, H. F. (2026). Mirogabalin Eliminated Pain and Reduced Inflammation in Visceral Pain. Physiological Research, 167. https://doi.org/10.33549/physiolres.935613
Vancouver
Yesilyurt I, Bitikas S, Yigit S, Gulakar B, Gul HF. Mirogabalin Eliminated Pain and Reduced Inflammation in Visceral Pain. Physiological Research. 2026:167. doi:10.33549/physiolres.935613
BibTeX
@article{Yesilyurt2026,
author = {Yesilyurt, I and Bitikas, S and Yigit, S and Gulakar, B and Gul, H Fatih},
title = {Mirogabalin Eliminated Pain and Reduced Inflammation in Visceral Pain},
journal = {Physiological Research},
year = {2026},
pages = {167},
doi = {10.33549/physiolres.935613}
}
EUVIMED